.css-1xsl8rf{width:100%;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;position:relative;overflow:hidden;background:var(--alert-bg);-webkit-padding-start:var(--chakra-space-4);padding-inline-start:var(--chakra-space-4);-webkit-padding-end:var(--chakra-space-4);padding-inline-end:var(--chakra-space-4);padding-top:var(--chakra-space-1);padding-bottom:var(--chakra-space-1);--alert-fg:var(--chakra-colors-orange-600);--alert-bg:var(--chakra-colors-orange-100);font-weight:var(--chakra-fontWeights-semibold);padding-left:var(--chakra-space-4);}.chakra-ui-dark .css-1xsl8rf:not([data-theme]),[data-theme=dark] .css-1xsl8rf:not([data-theme]),.css-1xsl8rf[data-theme=dark]{--alert-fg:var(--chakra-colors-orange-200);--alert-bg:rgba(251, 211, 141, 0.16);}@media screen and (min-width: 48em){.css-1xsl8rf{padding-left:var(--chakra-space-8);}}Please enable Javascript to use all features and improve your user experience.

Messoud Ashina

Chair

10 Dec
09:45 – 10:45
Plenary and EHF session
The involvement of PACAP in migraine pathogenesis
Strauss 2-3

Invited speaker

10 Dec
10:15 – 10:45 20 Min. 10 Min.
Invited lecture
The role of PACAP in migraine: Insights for clinical studies

Speaker

07 Dec
12:15 – 12:16 1 Min. 0 Min.
Waiting for On Demand
Reducing The Load Of Migraine Burden: The Burden Beyond Pain
09 Dec
16:15 – 16:20 3 Min. 2 Min.
ePoster
P266
Interim Analysis on the Effectiveness of Fremanezumab for the Preventive Treatment of Migraine: The Observational PEARL Study
CGRP inhibitors in the clinic, Migraine
09 Dec
16:35 – 16:40 3 Min. 2 Min.
ePoster
P270
Past Preventive Migraine Treatment in Patients Initiating Fremanezumab in Clinical Practice: Interim Data from the PEARL Study
CGRP inhibitors in the clinic, Migraine

Further involvements

07 Dec
14:05 – 14:15 8 Min. 2 Min.
Abstract lecture
A3
Second messenger signaling bypasses blockade of the calcitonin gene-related peptide (CGRP) receptor to provoke migraine attacks in humans
Basic science, animal models in headache research, Migraine
08 Dec
13:45 – 13:55 8 Min. 2 Min.
Abstract lecture
A13
One-quarter of individuals with weekly headache have never consulted a medical doctor: A Danish nationwide cross-sectional survey
Epidemiology, Guidelines in headache
08 Dec
16:00 – 16:05 3 Min. 2 Min.
ePoster
P38
Characterization of adult patients with status migrainosus in a tertiary hospital in Colombia, 2019-2021
Epidemiology, Migraine
08 Dec
16:10 – 16:15 3 Min. 2 Min.
ePoster
P40
PACAP signaling is not involved in GTN- and levcromakalim-induced hypersensitivity in mouse models of migraine
Migraine
08 Dec
16:35 – 16:40 3 Min. 2 Min.
ePoster
P20
Cluster Headache – The Worst Possible Pain on YouTube
Cluster headache
08 Dec
16:45 – 16:50 3 Min. 2 Min.
ePoster
P91
Glibenclamide posttreatment does not inhibit levcromakalim induced headache: A randomized clinical trial
Migraine, Neuropeptides, channels in headache
09 Dec
15:30 – 15:35 3 Min. 2 Min.
ePoster
P137a
Long-Term Treatment With Lasmiditan in Patients With Migraine: Results From the Open-Label Extension of the CENTURION Study
Migraine
09 Dec
15:30 – 15:35 3 Min. 2 Min.
ePoster
P242
Prevalence of neck pain in migraine: A systematic review and meta-analysis
Epidemiology, Migraine
09 Dec
15:35 – 15:40 3 Min. 2 Min.
ePoster
P103
Atogepant for the preventive treatment of chronic migraine: results from the PROGRESS phase 3 trial
Migraine
09 Dec
15:45 – 15:50 3 Min. 2 Min.
ePoster
P141
Safety and tolerability of atogepant: a post hoc analysis of pooled data from four clinical trials
Migraine
09 Dec
16:05 – 16:10 3 Min. 2 Min.
ePoster
P250
Barriers and gaps in headache education: a national cross-sectional survey of neurology residents in Denmark
Epidemiology, Guidelines in headache
09 Dec
16:15 – 16:20 3 Min. 2 Min.
ePoster
P129
Atogepant for the Preventive Treatment of Chronic Migraine in Europe: Results From the PROGRESS Study
Migraine
09 Dec
16:15 – 16:20 3 Min. 2 Min.
ePoster
P111
Eptinezumab for Migraine Prevention in Patients with 2-4 Prior Treatment Failures: DELIVER Subpopulation Analysis
Migraine
09 Dec
16:15 – 16:20 3 Min. 2 Min.
ePoster
P266
Interim Analysis on the Effectiveness of Fremanezumab for the Preventive Treatment of Migraine: The Observational PEARL Study
CGRP inhibitors in the clinic, Migraine
09 Dec
16:20 – 16:25 3 Min. 2 Min.
ePoster
P112
Efficacy and Safety of Eptinezumab for Migraine Prevention in Patients With 2–4 Prior Preventive Treatment Failures
Migraine
09 Dec
16:35 – 16:40 3 Min. 2 Min.
ePoster
P116
Adenosine causes short-lasting vasodilation and headache, but not migraine attacks in migraine patients: A randomized clinical trial
Headache, hormones and dietary, Migraine
09 Dec
16:35 – 16:40 3 Min. 2 Min.
ePoster
P270
Past Preventive Migraine Treatment in Patients Initiating Fremanezumab in Clinical Practice: Interim Data from the PEARL Study
CGRP inhibitors in the clinic, Migraine
09 Dec
16:40 – 16:45 3 Min. 2 Min.
ePoster
P117
Treatment Responder Rates of Oral Atogepant for the Preventive Treatment of Chronic Migraine: Results From the PROGRESS Trial
Migraine
10 Dec
08:10 – 08:20 8 Min. 2 Min.
Abstract lecture
A37
Arterial responses to infusion of glucagon-like peptide-1 in humans: A randomized trial study
Migraine, Neuropeptides, channels in headache